- Report
- January 2025
- 132 Pages
Global
From €868EUR$950USD£740GBP
- Report
- January 2025
- 132 Pages
Global
From €868EUR$950USD£740GBP
- Report
- November 2018
- 56 Pages
Global
From €6851EUR$7,500USD£5,842GBP
- Report
- July 2024
- 280 Pages
Global
From €1698EUR$1,859USD£1,448GBP
€2425EUR$2,655USD£2,068GBP
- Report
- May 2023
- 252 Pages
Global
From €2283EUR$2,499USD£1,947GBP
€3261EUR$3,570USD£2,781GBP
- Report
- July 2022
- 176 Pages
Global
From €2210EUR$2,419USD£1,884GBP
€3157EUR$3,456USD£2,692GBP
- Report
- July 2022
- 280 Pages
Global
From €2210EUR$2,419USD£1,884GBP
€3157EUR$3,456USD£2,692GBP
- Report
- April 2022
- 210 Pages
Global
From €2210EUR$2,419USD£1,884GBP
€3157EUR$3,456USD£2,692GBP
- Book
- April 2018
- 248 Pages
The Breast Cancer market is a subset of the Women's Health market, focusing on the diagnosis, treatment, and prevention of breast cancer. It includes a range of products and services, from medical devices and pharmaceuticals to patient education and support. Breast cancer is the most common cancer among women worldwide, and the market is driven by the need to improve early detection and treatment outcomes.
The Breast Cancer market is highly competitive, with a range of players from large multinationals to small start-ups. Companies in the market include Roche, Novartis, AstraZeneca, Pfizer, Merck, and Johnson & Johnson, as well as smaller players such as Myriad Genetics, Genomic Health, and Natera. Show Less Read more
